Somewhat Positive News Coverage Somewhat Unlikely to Affect Allena Pharmaceuticals (ALNA) Stock Price

News coverage about Allena Pharmaceuticals (NASDAQ:ALNA) has trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Allena Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.470282097001 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the headlines that may have impacted Accern Sentiment’s analysis:

Several brokerages recently commented on ALNA. Wedbush began coverage on Allena Pharmaceuticals in a research note on Monday, November 27th. They issued an “outperform” rating and a $30.00 price target for the company. Cowen assumed coverage on Allena Pharmaceuticals in a research note on Monday, November 27th. They issued an “outperform” rating for the company. Jefferies Group assumed coverage on Allena Pharmaceuticals in a report on Monday, November 27th. They issued a “buy” rating and a $22.00 target price for the company. Finally, Credit Suisse Group assumed coverage on Allena Pharmaceuticals in a report on Monday, November 27th. They issued an “outperform” rating and a $22.00 target price for the company.

Allena Pharmaceuticals (NASDAQ ALNA) traded up $0.15 on Monday, reaching $14.00. The company had a trading volume of 99,500 shares, compared to its average volume of 102,435. Allena Pharmaceuticals has a 12-month low of $8.66 and a 12-month high of $15.00.

In other news, Director James N. Topper bought 500,000 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $7,000,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Bessemer Venture Partners Vii bought 36,000 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was purchased at an average price of $14.00 per share, with a total value of $504,000.00. The disclosure for this purchase can be found here.

TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Allena Pharmaceuticals (ALNA) Stock Price” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.com-unik.info/2017/12/04/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-allena-pharmaceuticals-alna-stock-price.html.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.

What are top analysts saying about Allena Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Allena Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit